Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA CRC-203
NCT07221357Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Primary completion
- Feb 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of pumitamig in colorectal cancer (CRC), sponsored by Bristol Myers Squibb. Started Dec 2025; status: recruiting.
02
Drugs
pumitamig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07221357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221357.